Zhenge Bio is a macromolecular biopharmaceutical research and development company. Its core business is macromolecule biopharmaceutical research and development, CDMO services (including cell line development, process development and engineering scale-up, pilot production, drug IND and BLA filing, process characterization and validation, etc. ), project transfer, development and production of mammalian cell culture medium, etc. Recently, Zhenge Bio announced the completion of RMB 100 million C+ round of financing, which was jointly completed by Sinopharm Zhongjin, Zhangke Herun, Lingang Lanwan Capital, Pudong Science and Technology Innovation, and Haiwang Capital.
This article is reproduced from: https://www.itjuzi.com/investevent/13489958
This site is for inclusion only, and the copyright belongs to the original author.